-
Abstract Number: 0570
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
-
Abstract Number: 0571
Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
-
Abstract Number: 0572
Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects
-
Abstract Number: 0573
Characteristics of Difficult-to-Treat Ankylosing Spondylitis- Results from Real-World Data
-
Abstract Number: 0574
14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
-
Abstract Number: 0575
Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA
-
Abstract Number: 0576
Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up
-
Abstract Number: 0577
AMH Titers in Women with Axial Spondyloarthritis Are Significantly Lower Compared to the General Population: An Analysis of the 10-year Follow-up of the DESIR Cohort
-
Abstract Number: 0578
Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort
-
Abstract Number: 0579
Association of the Presence of Active Acute Anterior Uveitis with Disease Activity in Axial Spondyloarthritis
-
Abstract Number: 0580
Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis
-
Abstract Number: 0581
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
-
Abstract Number: 0582
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
-
Abstract Number: 0583
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
-
Abstract Number: 0584
Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 181
- Next Page »